{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"VGPR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"PR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"Response that was confirmed on 2 consecutive evaluations.\\>\n\n* Complete Response (CR): Complete disappearance of M-protein from serum and urine on immunofixations, normalization of Free Light Chain (FLC) ratio and \\<=5% plasma cells in bone marrow\\>\n* Very Good Partial Response (VGPR): \\>=90% reduction in serum M-spike, Urine M-spike \\<100mg per 24 hours\\>\n* Partial Response (PR): \\>=50% reduction in serum M-spike, Urine M-spike \\>=90% reduction or \\< 200mg per 24 hours, or \\>=50% decrease in difference between involved and uninvolved FLC levels or 50% decrease in bone marrow plasma cells","groups":[{"description":"Intervention: Drug: lenalidomide 10 mg orally days 1-21 every 28 days until progression\\> \\> Intervention: Drug: melphalan 5mg/m\\^2 orally days 1-4 every 28 days until progression\\>\n\n\\> Intervention: Drug: prednisone 60mg/m\\^2, orally days 1-4 every 28 days until progression","id":"OG000","title":"Treatment (Lenalidomide, Melphalan, Prednisone)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Every cycle during treatment","title":"Patients With Overall Confirmed Response","type":"PRIMARY","unitOfMeasure":"participants"}